Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VXA-CoV2-1, an oral tablet COVID-19 vaccine triggers mucosal immune responses in humans, is believed to be the first defense against airborne viruses, such as coronavirus and flu.
Lead Product(s): VXA-CoV2-1.1-S
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1.1-S
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Vaxart
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutical development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 26, 2021